CCO-Lung-Fellows-Thatcher-LO-鳞癌.pptVIP免费

Slideseton:ThatcherN,HirschFR,LuftAV,etal.Necitumumabplusgemcitabineandcisplatinversusgemcitabineandcisplatinaloneasfirst-linetherapyinpatientswithstageIVsquamousnon-small-celllungcancer(SQUIRE):anopen-label,randomized,controlledphase3trial.LancetOncol.2015;16:763-774.SQUIRE:ImprovedSurvivalWithNecitumumab+Gemcitabine/CisplatinvsGemcitabine/CisplatinasFirst-lineTreatmentinPatientsWithSquamousNSCLCThisactivityissupportedbyeducationalgrantsfromGenentech,Lilly,andNovartisPharmaceuticalsCorporation.AboutTheseSlidesUsersareencouragedtousetheseslidesintheirownnoncommercialpresentations,butweaskthatcontentandattributionnotbechanged.UsersareaskedtohonorthisintentTheseslidesmaynotbepublishedorpostedonlinewithoutpermissionfromClinicalCareOptions(emailpermissions@clinicaloptions.com)DisclaimerThematerialspublishedontheClinicalCareOptionsWebsitereflecttheviewsoftheauthorsoftheCCOmaterial,notthoseofClinicalCareOptions,LLC,theCMEproviders,orthecompaniesprovidingeducationalgrants.ThematerialsmaydiscussusesanddosagesfortherapeuticproductsthathavenotbeenapprovedbytheUnitedStatesFoodandDrugAdministration.Aqualifiedhealthcareprofessionalshouldbeconsultedbeforeusinganytherapeuticproductdiscussed.Readersshouldverifyallinformationanddatabeforetreatingpatientsorusinganytherapiesdescribedinthesematerials.Background:NecitumumabinAdvancedSquamousNSCLCPlatinum-baseddoubletchemotherapylongtimestandardfirst-linetreatmentoptionforthe~30%ofptswithsquamousNSCLC[1]Necitumumab:fullyhumanIgG1anti–EGFRmAb–Additiontogemcitabine/cisplatinincreasedantitumoractivityinmousexenograftmodelsofNSCLC[2]–FailedtoimproveOSwhenaddedtopemetrexed/cisplatininptswithadvancednonsquamousNSCLCinphaseIIIINSPIREtrial[3]PhaseIIISQUIREtrialevaluatedsafety,efficacyofnecitumumab+gemcitabine/cisplatinvsgemcitabine/cisplatininchemotherapy-naiveptswithstageIVsquamousNSCLC[1]1.ThatcherN,etal.LancetOncol.2015;16:763-774.2.SamakogluS,etal.CancerGenomicProteomics.2012;9:77-92.3.Paz-AresL,etal.LancetOncol.2015;16:328-3...